Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 2154
Journal of Biotechnology & Biomaterials received 2154 citations as per Google Scholar report
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- ResearchBible
- China National Knowledge Infrastructure (CNKI)
- Access to Global Online Research in Agriculture (AGORA)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
In Association with
Synthetic mRNAs in clinical trials: Manufacturing of high quality GMP grade synthetic mRNAs
Joint Event on 22nd Global Congress on Biotechnology & 5th International Conference on Enzymology and Protein Chemistry
Guido Krupp
AmpTec GmbH, Germany
Keynote: J Biotechnol Biomater
Abstract
Synthetic mRNAs from AmpTec have achieved a world-wide acceptance. AmpTec’s mRNAs are available as GMP grade products and have been introduced in several clinical trials in Europe, Australia and USA. Availability of high quality synthetic mRNAs is crucial in enabling significant progress in this field. Worldwide, a very limited number of active manufacturers of high quality mRNAs, AmpTec continues to realize its obligation to support the entry of new players by providing customized, mRNA products at small and large scales, from mg to grams. Applications of synthetic mRNA include reprogramming of human cells; antigen expression for vaccination projects in oncogenesis, infectious disease and allergy prevention; protein-replacement therapies. In a recent overview, applications and corresponding synthetic mRNA quality requirements were presented by Quabius & Krupp in New Biotechnology 2015. Syn-mRNAs can be generated by in vitro transcription (IVT) from defined templates containing the synthetic gene of interest. Optimal mRNA activity depends on a long, unmasked poly(A) tail, but long hompolymeric sequence are not reliably propagated in E.coli. Our alternative procedure uses PCR products as IVT-templates resulting in very well defined and easily modified poly(A) tails. Possible problems: Challenging sequences can lead to poor results in generation of the PCR template (AmpTec workflow) or (ii) during in vitro transcription reactions (workflow of all current mRNA manufacturers). For both steps (i) and (ii), results and trouble shooting are presented. Quality requirements and QC methods for GMP-grade synthetic mRNAs in therapeutic applications are presented.Biography
Guido Krupp is a CEO and President of AmpTec GmbH. He received his PhD Degree from Würzburg University and Max-Planck-Institute Martinsried in 1981. He was Postdoc at Yale University from 1983 to 1987. He was a Research Group Leader at Kiel University from 1987 to 2002 and Founder of artus GmbH, 1998 and AmpTec GmbH, 2005 and KSK Diagnostics GmbH, 2015. His research interests include nucleic acid technology with focus on RNA, plant pathogens (viroids), ribozymes and telomerase. He has more than 60 publications, Editor of “Ribozyme Biochemistry and Biotechnology” and Editorial Board of “Biotechnology Annual Review”.
E-mail: krupp@amp-tec.com
